Yoshida T, Saeki T, Ohashi S, Okudaira T, Lee M, Yoshida H, Maruoka H, Ito H, Funasaka S, Kato H
Department of Otolaryngology Head and Neck Surgery, Tokyo Medical College.
Nihon Jibiinkoka Gakkai Kaiho. 1995 May;98(5):795-804. doi: 10.3950/jibiinkoka.98.795.
Photodynamic therapy (PDT) is an innovative treatment involving the use of a photosensitizer and low powered laser to selectively destroy tumor cells. In the head and neck, its application to laryngeal papilloma, metastatic tumor and oral cancer have been reported but our report on PDT for laryngeal cancer is the only clinical report in Japan. At present, we treat laryngeal cancer by PDT using argon and excimer dye lasers such as the HpD. In the present study, we assessed the utility and safety of PDT and investigated long-term prognosis after this therapy. The subjects were 12 patients with laryngeal cancer who underwent PDT between February 1988 and October 1993. Among them, ten with cancer of the vocal cords underwent PDT as the primary treatment and two underwent PDT because of recurrence after radiotherapy. Under local anesthesia, PDT was performed using a video endoscope (Pentax EB2000). The optimal dose from an argon dye laser was set at 200-500 mW/cm2 of continuous waves for 20 minutes and that from the excimer dye laser was set at 200 J/cm2 of pulse waves (3-4 mJ/pulse, 30-40 Hz). The argon dye laser used was the Fujinon PDT developed by Fuji Photo Optical Co., Ltd. The excimer dye laser used was a product of Hamamatsu Photonics Co., Ltd. 1) Effect of PDT The effect of PDT as a primary treatment for ten patients was classified as CR in eight and PR in two cases, the CR rate being 80.0%. When evaluated only for T1 patients, the results were classified as CR in eight and PR in one. The patient whose response was classified as PR had refused repeated PDT. CR was maintained for five and 13 months in the two patients who underwent PDT as a secondary treatment after radiotherapy. CR was obtained in 83.3% of all patients studied. 2) Duration of the effect of PDT and long-term prognosis The patients were followed up for 14 to 71 months. The longest duration of CR achieved by PDT monotherapy was 65 months. Among the patients who underwent PDT as a primary treatment, one developed local recurrence and underwent radiotherapy. However, the prognosis was uneventful in all other patients. CR after PDT monotherapy was maintained for 42 months in one T3 patient. Two patients with a history of previous treatment thereafter relapsed and underwent total laryngectomy. The larynx could be conserved in 83.3% of all patients. However, it could be conserved in 100% of patients who underwent PDT as a primary treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
光动力疗法(PDT)是一种创新治疗方法,涉及使用光敏剂和低功率激光来选择性地破坏肿瘤细胞。在头颈部,其在喉乳头状瘤、转移性肿瘤和口腔癌中的应用已有报道,但我们关于PDT治疗喉癌的报告是日本唯一的临床报告。目前,我们使用氩激光和准分子染料激光(如血卟啉衍生物)对喉癌进行PDT治疗。在本研究中,我们评估了PDT的效用和安全性,并调查了该治疗后的长期预后。研究对象为1988年2月至1993年10月期间接受PDT治疗的12例喉癌患者。其中,10例声带癌患者接受PDT作为主要治疗,2例因放疗后复发接受PDT治疗。在局部麻醉下,使用视频内窥镜(宾得EB2000)进行PDT治疗。氩染料激光的最佳剂量设定为连续波200 - 500 mW/cm²,持续20分钟,准分子染料激光的最佳剂量设定为脉冲波200 J/cm²(3 - 4 mJ/脉冲,30 - 40 Hz)。使用的氩染料激光是富士写真光机株式会社开发的藤仓PDT。使用的准分子染料激光是滨松光子株式会社的产品。1)PDT的效果 10例患者作为主要治疗的PDT效果,8例为完全缓解(CR),2例为部分缓解(PR),CR率为80.0%。仅对T1期患者评估时,结果为8例CR,1例PR。反应为PR的患者拒绝重复PDT治疗。放疗后作为二线治疗接受PDT的2例患者,CR分别维持了5个月和13个月。所有研究患者的CR率为83.3%。2)PDT效果的持续时间和长期预后 对患者进行了14至71个月的随访。PDT单一疗法达到的最长CR持续时间为65个月。在作为主要治疗接受PDT的患者中,1例发生局部复发并接受了放疗。然而,其他所有患者的预后均平稳。1例T3期患者PDT单一疗法后的CR维持了42个月。此后,2例有既往治疗史的患者复发并接受了全喉切除术。所有患者中83.3%的喉得以保留。然而,作为主要治疗接受PDT的患者中,100%的喉得以保留。(摘要截断于400字)